A new bioabsorbable sleeve for lung staple-line reinforcement (FOREsealTM):: report of a three-center phase II clinical trial

被引:15
|
作者
Thomas, Pascal
Massard, Gilbert
Porte, Henri
Doddoli, Christophe
Ducrocq, Xavier
Conti, Massimo
机构
[1] Univ Hosp Marseille, Dept Thorac Surg, Marseille, France
[2] Univ Hosp Strasbourg, Dept Thorac Surg, Strasbourg, France
[3] Univ Hosp Lille, Dept Thorac Surg, Lille, France
关键词
lung surgery; new technology;
D O I
10.1016/j.ejcts.2006.01.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate on the feasibility, safety, and effectiveness of a new bioabsorbable material for lung staple-tine reinforcement. Methods: This prospective open trial included 66 patients (mean age of 56 +/- 17 years) who underwent various types of lung resection using staplers with knitted calcium alginate sleeves for buttressing (FOREseal (TM), Laboratoires Brothier, Nanterre, France) at three academic centers: 29 lobectomies, 22 emphysema surgeries, 15 wedge resections or lung biopsies. Intraoperative air leakage was assessed at a mean respiratory peak pressure of 30 cmH(2)O, and rated as grade 1, 2, or 3. Persistent air leakage in the postoperative course, as well as any relevant event, was assessed daily. The follow-up period was of 6 months. Results: No technical problem linked to the device occurred. Hemostasis of the cutting edges was completed in all patients. Fifty-six percent of the patients had no intraoperative air leak and 27.3% had grade 1 leaks. Mean postoperative air leaks and thoracic drainage times were 1.9 +/- 2.3 days and 6 +/- 5.3 days, respectively. In-hospital mortality was nit. There was no empyema. Mean hospital stay was 9.1 +/- 6.6 days. At follow-up, one patient underwent lung transplantation, and pathology of the explanted specimen showed the absence of device-related foreign-body inflammation. One patient complained from metalloptysis, and another one, with a metastatic invasive aspergillosis, developed an infectious recurrence that required reoperation. Conclusions: FOREseal is an ergonomic, safe, and promising new material instead of nonabsorbable materials and xenomaterials for staple-tine reinforcement. A randomized comparative study is now in progress. (c) 2006 Elsevier B.V. All. rights reserved.
引用
收藏
页码:880 / 885
页数:6
相关论文
共 50 条
  • [41] Phase II study of amrubicin (AMR) for patients (pts) with non-small cell lung cancer (NSCLC) as third-line or fourth-line chemotherapy: Hokkaido Lung Cancer Clinical Study Group trial (HOT) 0901.
    Harada, Toshiyuki
    Ito, Kenichiro
    Takamura, Kei
    Kikuchi, Eiki
    Oizumi, Satoshi
    Kuda, Tomoya
    Sugawara, Shunichi
    Maemondo, Makoto
    Fujita, Yuka
    Kinoshita, Ichiro
    Inoue, Akira
    Hommura, Fumihiro
    Katsuura, Yutaka
    Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Aripazine reverses unfractionated and low molecular weight heparins, fondaparinux and new Xa and IIa oral anticoagulants: report of Phase I/II clinical trial with edoxaban
    Ansell, J. E.
    Laulicht, B.
    Bakhru, S.
    Steiner, S.
    Noveck, R.
    Brown, K.
    Grosso, M.
    Morishima, Y.
    Dishy, V.
    Mercuri, M.
    EUROPEAN HEART JOURNAL, 2014, 35 : 854 - 855
  • [43] Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)
    Iranzo, Vega
    Sirera, Rafael
    Carrato, Alfredo
    Cabrera, Andrea
    Jantus, Eloisa
    Guijarro, Ricardo
    Sanmartin, Elena
    Blasco, Ana
    Gil, Mireia
    Gomez-Aldaravi, Lorenzo
    Luis Gonzalez-Larriba, Jose
    Massuti, Bertomeu
    Velasco, Amalia
    Provencio, Mariano
    Rosell, Rafael
    Camps, Carlos
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (06): : 411 - 418
  • [44] Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)
    Vega Iranzo
    Rafael Sirera
    Alfredo Carrato
    Andrea Cabrera
    Eloísa Jantus
    Ricardo Guijarro
    Elena Sanmartín
    Ana Blasco
    Mireia Gil
    Lorenzo Gómez-Aldaraví
    José Luis González-Larriba
    Bertomeu Massuti
    Amalia Velasco
    Mariano Provencio
    Rafael Rosell
    Carlos Camps
    Clinical and Translational Oncology, 2011, 13 : 411 - 418
  • [45] A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
    Yang, Jin-Ji
    Huang, Cheng
    Chen, Gong-Yan
    Song, Yong
    Cheng, Ying
    Yan, Hong-Hong
    Zhou, Qing
    Wu, Yi-Long
    BMC CANCER, 2014, 14
  • [46] A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
    Jin-Ji Yang
    Cheng Huang
    Gong-Yan Chen
    Yong Song
    Ying Cheng
    Hong-Hong Yan
    Qing Zhou
    Yi-Long Wu
    BMC Cancer, 14
  • [47] Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial
    Xiang, Miao
    Yang, Xiyue
    Ren, Surong
    Du, Huan
    Geng, Lidan
    Yuan, Li
    Wen, Yixue
    Lin, Binwei
    Li, Jie
    Zhang, Yu
    Feng, Gang
    Du, Xiaobo
    ONCOLOGIST, 2021, 26 (12): : E2130 - E2135
  • [48] Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC)
    Faoro, L.
    Cohen, E. E.
    Govindan, R.
    Kozloff, M. F.
    Hoffman, P. C.
    Maitland, M. L.
    Verel, K.
    Szeto, L.
    Salgia, R.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial
    Dong, Weigang
    Yin, Yan
    Liu, Bin
    Jiang, Yan
    Wang, Lei
    Shi, Dongsheng
    Qin, Jianwen
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [50] Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer
    Laskin, J. J.
    Pugh, T.
    Jackson, C.
    Sutcliffe, M.
    Ionescu, D.
    Melosky, B.
    Ho, C.
    Sun, S.
    Murray, N.
    Marra, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)